- CYCLIN-DEPENDENT KINASE INHIBITORS
-
Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.
- -
-
Page/Page column 204
(2020/07/15)
-
- Investigation of biaryl heterocycles as inhibitors of Wee1 kinase
-
In continuation of our previous research towards the discovery of potent, selective and drug-like Wee1 inhibitors, 2 novel series of biaryl heterocycles were designed, synthesized and evaluated. The new biaryl cores were designed to enable structure?activ
- Mastracchio, Anthony,Lai, Chunqiu,Torrent, Maricel,Bromberg, Kenneth,Buchanan, Fritz G.,Ferguson, Debra,Bontcheva, Velitchka,Johnson, Eric F.,Lasko, Loren,Maag, David,Soni, Nirupama,Shoemaker, Alexander R.,Penning, Thomas D.
-
p. 1481 - 1486
(2019/04/25)
-
- C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant
-
The development of specific kinase inhibitors has been a long-standing challenge in chemical biology and drug discovery. We have successfully discovered a series of C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific inhibitors against the clinical resistance-related EGFRT790M mutant. One of the most promising compounds, 9f, tightly binds to the EGFRT790M mutant and strongly inhibits its enzymatic function with an IC50 value of 0.80 nM, and displays an extraordinary target specificity with S(35) and S(10) selectivity scores of 0.005 and 0.000, respectively, in a kinase selectivity profiling study against 456 different kinases at 100 nM. The compound also selectively suppresses the proliferation of EGFRT790M mutated H1975 NSCLC cells with an IC50 value of 2.80 nM, but is significantly less toxic to cells with wild-type EGFR. Compound 9f may serve as a promising lead compound for drug discovery overcoming the acquired resistance of NSCLC patients without adverse toxicities.
- Xu, Tianfeng,Peng, Ting,Ren, Xiaomei,Zhang, Lianwen,Yu, Lei,Luo, Jinfeng,Zhang, Zhang,Tu, Zhengchao,Tong, Linjiang,Huang, Zhaoru,Lu, Xiaoyun,Geng, Meiyu,Xie, Hua,Ding, Jian,Ding, Ke
-
supporting information
p. 1693 - 1697
(2015/09/21)
-
- 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE
-
The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.
- -
-
Page/Page column 82
(2008/12/05)
-